AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
AbbVie (NYSE:ABBV) has announced a $195 million investment to expand its active pharmaceutical ingredient (API) manufacturing facility in North Chicago, Illinois. This expansion is part of AbbVie's broader $10 billion U.S. investment commitment over the next decade.
Construction of the new API facility will begin in fall 2025 and is expected to be fully operational by 2027. The expansion will enhance AbbVie's chemical synthesis capabilities for neuroscience, immunology, and oncology medicines, while supporting over 6,000 American jobs across 11 manufacturing sites.
AbbVie (NYSE:ABBV) ha annunciato un investimento di 195 milioni di dollari per ampliare il suo stabilimento di produzione di principi attivi (API) a North Chicago, Illinois. Questa espansione fa parte del pi霉 ampio impegno di investimento negli USA di 10 miliardi di dollari di AbbVie per il prossimo decennio.
I lavori per il nuovo impianto API inizieranno nell'autunno 2025 e si prevede che saranno completamente operativi entro il 2027. L'ampliamento potenzier脿 le capacit脿 di sintesi chimica di AbbVie per farmaci in neuroscienze, immunologia e oncologia, sostenendo al contempo oltre 6.000 posti di lavoro negli Stati Uniti distribuiti su 11 siti produttivi.
AbbVie (NYSE:ABBV) ha anunciado una inversi贸n de 195 millones de d贸lares para ampliar su planta de fabricaci贸n de ingredientes farmac茅uticos activos (API) en North Chicago, Illinois. Esta expansi贸n forma parte del compromiso de inversi贸n en EE. UU. de 10.000 millones de d贸lares de AbbVie para la pr贸xima d茅cada.
La construcci贸n de la nueva planta de API comenzar谩 en el oto帽o de 2025 y se espera que est茅 completamente operativa para 2027. La ampliaci贸n mejorar谩 las capacidades de s铆ntesis qu铆mica de AbbVie para medicamentos en neurociencia, inmunolog铆a y oncolog铆a, al tiempo que apoyar谩 a m谩s de 6.000 empleos en Estados Unidos en 11 sitios de fabricaci贸n.
AbbVie (NYSE:ABBV)電� 鞚茧Μ雲胳澊欤� 雲胳姢 鞁滌勾瓿犾棎 鞛堧姅 頇滌劚 鞚橃暯頀� 靹彪秳(API) 鞝滌“ 鞁滌劋鞚� 頇曥灔頃橁赴 鞙勴暣 1鞏�9,500毵� 雼煬鞚� 韴瀽毳� 氚滍憸頄堨姷雼堧嫟. 鞚� 頇曥灔鞚� 頄ロ泟 10雲勱皠 氙戈淡 雮� 100鞏� 雼煬 韴瀽毳� 鞎届啀頃� AbbVie鞚� 甏戨矓鞙勴暅 瓿勴殟鞚� 鞚茧秬鞛呺媹雼�.
靸� API 鞁滌劋鞚� 瓯挫劋鞚� 2025雲� 臧�鞚�鞐� 鞁滌瀾霅橂┌ 2027雲勱箤歆� 鞕勳爠 臧�霃�霅� 瓴冹溂搿� 鞓堨儊霅╇媹雼�. 鞚措矆 頇曥灔鞚� 鞁犼步瓿柬暀, 氅挫棴頃� 氚� 膦呾枒頃� 鞚橃暯頀堨潣 頇旐暀 頃╈劚 鞐焿鞚� 臧曧檾頃橁碃, 11臧� 鞝滌“ 鞁滌劋 鞝勲皹鞐愳劀 6,000臧� 鞚挫儊鞚� 氙戈淡 雮� 鞚检瀽毽�毳� 歆�鞗愴暊 瓴冹瀰雼堧嫟.
AbbVie (NYSE:ABBV) a annonc茅 un investissement de 195 millions de dollars pour agrandir son site de production d'ingr茅dients pharmaceutiques actifs (API) 脿 North Chicago, dans l'Illinois. Cette extension s'inscrit dans le plan d'investissement de 10 milliards de dollars aux 脡tats-Unis d'AbbVie pour la prochaine d茅cennie.
La construction de la nouvelle usine API d茅butera 脿 l'automne 2025 et devrait 锚tre enti猫rement op茅rationnelle d'ici 2027. L'agrandissement renforcera les capacit茅s de synth猫se chimique d'AbbVie pour des m茅dicaments en neurosciences, immunologie et oncologie, tout en soutenant plus de 6 000 emplois am茅ricains r茅partis sur 11 sites de production.
AbbVie (NYSE:ABBV) hat eine Investition von 195 Millionen US-Dollar angek眉ndigt, um sein Werk zur Herstellung von Wirkstoffen (API) in North Chicago, Illinois, zu erweitern. Diese Erweiterung ist Teil von AbbVie's umfassendem 10鈥惭颈濒濒颈补谤诲别苍鈥慤厂鈥慏辞濒濒补谤鈥慖苍惫别蝉迟颈迟颈辞苍蝉惫别谤蝉辫谤别肠丑别苍 in den USA f眉r das n盲chste Jahrzehnt.
Der Bau der neuen API-Anlage beginnt im Herbst 2025 und soll bis 2027 voll betriebsbereit sein. Die Erweiterung wird AbbVies chemische Synthesef盲higkeiten f眉r Medikamente in den Bereichen Neurowissenschaften, Immunologie und Onkologie verbessern und zugleich 眉ber 6.000 Arbeitspl盲tze in den USA an 11 Produktionsstandorten unterst眉tzen.
- Part of larger $10 billion capital investment commitment in the U.S.
- Expansion of domestic API manufacturing capabilities for critical medicines
- Creation of additional jobs supporting 6,000+ existing American manufacturing positions
- Strategic enhancement of U.S. pharmaceutical production capabilities
- Significant capital expenditure of $195 million
- Long implementation timeline with facility not operational until 2027
Insights
AbbVie's $195M API facility strengthens domestic supply chain security while advancing their long-term U.S. manufacturing strategy.
AbbVie's
The investment is strategically timed as part of AbbVie's larger
Chemical synthesis capabilities expansion signals AbbVie's focus on complex small molecule drugs alongside its biologics portfolio. This balanced approach to manufacturing investments shows management's forward-thinking strategy in maintaining flexibility across different therapeutic modalities.
The 2027 operational timeline indicates a comprehensive build with cutting-edge capabilities, not merely an incremental capacity expansion. This positions AbbVie to meet growing regulatory preferences for domestic pharmaceutical production while potentially capturing manufacturing incentives as governments increasingly view pharmaceutical manufacturing as a national security priority.
While the
- New
$195 million U.S. - Expansion is part of听AbbVie's previously announced commitment to invest more than
$10 billion U.S. over the next decade - Construction will begin in fall 2025 with the site expected to be fully operational in 2027
- Furthers听AbbVie's long-term commitment to the
U.S. expanding the company'sNorth Chicago workforce and critical manufacturing capabilities
Active pharmaceutical ingredient manufacturing is a complex and multi-step process that involves producing the active components responsible for the therapeutic effects of medications. The new North Chicago API facility will expand AbbVie's chemical synthesis capabilities in the
"Over the next decade, AbbVie will expand production of API, drug product, peptides and medical devices in the
Construction of the new North Chicago API facility will begin in fall 2025, with the site projected to be听fully operational in 2027. The facility will expand AbbVie's existing
This investment furthers AbbVie's long-term commitment to
"AbbVie's decision to expand its manufacturing footprint in
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care 鈥� and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on 听, , and
Media: Gabby Tarbert听 听 | Investors: Liz Shea (847) 935-2211 |
听
View original content to download multimedia:
SOURCE AbbVie
FAQ
How much is AbbVie investing in its North Chicago API manufacturing facility?
When will AbbVie's new North Chicago manufacturing facility be operational?
How many jobs does AbbVie's U.S. manufacturing operations support?
What is the total amount AbbVie plans to invest in the U.S. over the next decade?
What types of medicines will be produced at AbbVie's new North Chicago facility?
